

4TECH

4TECH is dedicated to restoring the quality of life for patients suffering from Tricuspid Valve regurgitation and has developed a proprietary transcatheter solution for the treatment of TR. Because of its unique anchoring and tensioning mechanism, the 4TECH TriCinch™ Coil System for Transcatheter Tricuspid Valve Repair (TTVR) potentially allows a simple and reproducible percutaneous procedure. In collaboration with key experts in the Structural Heart field, 4TECH is pioneering clinically advanced technology that offers an alternative solution for physicians and their patients suffering from tricuspid regurgitation. 4TECH Cardio Inc. is a Delaware, USA registered Company with primary operations under 4TECH Cardio Ltd, based in Galway Ireland.

Tom Fleming, CEO
www.4techtricuspid.com

Angel Valve

Angel Valve Project is dedicated to the development of sophisticated treatment concepts for mitral valve repair. The primary focus is the Mitral Butterfly® implant for mitral valve prolapse, invented by Werner Mohl, an academic cardiac surgeon with longstanding experience in surgical repair of the mitral valve. The Vienna based start-up is a spinoff of the Medical University Vienna. A platform of implants for percutaneous mitral valve repair using modular technology has been developed by the team to facilitate a shorter, low-risk procedure for FMR & DMR.

Prof. Werner Mohl, Founder & Chairman
Tamara McIntosh, Managing Director
Johanna Ticar, R&D Manager
tel. +43 664 160 0224
www.angelvalve.com

Cephea

Cephea Valve Technologies, Inc. is a Silicon Valley based medical device company developing innovative, minimally invasive valve replacement technologies. The company's first product is designed to treat patients who suffer from mitral valve disease. The mitral valve is catheter delivered by trans-septal access and encompasses suspension technology and self-centering features.

Dr. Juan Granada, Co-Founder and CMO
jgranada@crf.org
Mr. Thierry Thaire, Co-Founder and CEO
thierry@cephea.com

CoreMedic

CoreMedic is dedicated to developing ChordArt, the first transfemoral system for mitral valve chordal repair in the beating heart. ChordArt offers a first line therapy option for patients with mitral valve dysfunction and represents a less invasive procedure compared to the current surgical methods with open-chest or trans-apical access. ChordArt is designed to allow mitral repair in a wider patient population and is currently under clinical evaluation in European clinics. CoreMedic is a privately held medical device company headquartered in Radolfzell, Germany with a subsidiary in Biel/Bienne, Switzerland. CoreMedic is EN ISO 13485 certified.

Thomas Bauer, CEO

thomas.bauer@coremedic.ch

tel. +41(0)798740805

www.coremedic.ch

CroïValve

CroïValve is developing a transcatheter device to treat Tricuspid Regurgitation, a large unmet clinical need. CroïValve's patented solution employs coaptation enhancement to restore tricuspid valve function by supporting the native valve leaflets. CroïValve's aim is to be safer, more effective, less traumatic, and easier to deliver than competing technologies. CroïValve has proven the concept through extensive pre-clinical testing.

Lucy O'Keeffe, CEO

lucy@croivalve.com

tel. +353 87 915 0352

www.croivalve.com

InnovHeart

InnovHeart is a startup company incorporated in November 2015, with operational sites in Italy (Ivrea - TO) and US (Poway - CA). Company mission is to bring to patients a novel low-profile transcatheter mitral replacement device with a unique anchoring system: the Saturn Prosthesis. The project is in the pre-clinical phase with the trans-apical version, while the trans-septal system is under development. FHU is anticipated in H1 2019. The InnovHeart technology is protected by 6 families of patent applications. CEO is Giovanni Righini, having about 30 years of successful experience in bringing innovative implantable cardiac devices from feasibility to market.

Giovanni Righini, CEO

info@innovheart.com

www.innovheart.com

Mitre Medical

Mitre Medical Corp. is providing innovative solutions for cardiac surgeons and their patients presenting with functional MR. Mitre has developed the Mitral Touch® epicardial ring to provide cardiac surgeons an “Off-Pump” beating heart version of mitral annuloplasty. The goal is a less-invasive and predictive approach to treat functional MR. The Mitral Touch allows surgeons a concomitant MR treatment option for their existing CABG patients with moderate to severe MR. Mitre began enrolling patients in December 2017. Our feasibility phase demonstrated acute MR reduction and short surgical procedure times.

John MacMahon, CEO
JMacMahon@MitreMedical.com
www.MitreMedical.com

NaviGate

NaviGate Cardiac Structures, Inc. (NCSI) is an early-stage company focused on developing transcatheter solutions for treatment of atrioventricular valve regurgitation. Directed by Founder and Chief Executive Officer R.C. Quijano, M.D., Ph.D., the team at NaviGate has demonstrated that it is feasible to deliver and deploy its Atrioventricular Valved Stent (AVS) using the GATE™ System. To date, the AVS with GATE™ System has been utilized to treat compassionate use patients in the U.S. and abroad. NCSI is currently working towards authorization to initiate early feasibility studies for this novel and promising valve replacement technology. NCSI's headquarters are located at 20412 James Bay Circle, Lake Forest California, USA, 92630.

www.navigatecsi.com
tel. 949-238-6274

NeoChord

NeoChord is a privately held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation.

Mr. David Chung, President and CEO
info@NeoChord.com
www.neochord.com

New Valve Technology

New Valve Technology (NVT AG, Muri, Switzerland) is dedicated to developing and marketing innovative technologies for the minimally invasive treatment of all heart valves. Together with physicians and medical institutions, we pioneer safe and cost-effective therapies. Our long-term corporate view is founded on skilled engineering, fully integrated in-house production and quality at the highest level. Our vision is to help people with valvular heart disease live a healthier and more fulfilling life. With the current CE marked ALLEGRA Transcatheter Aortic Valve Implantation System, New Valve Technology offers a self-expanding valve with new capabilities for an easy, precise and controlled valve implantation.

Udo Scheiner, CEO
info@nvt-med.com
tel. +49(0) 7471 989 79-0
www.nvt-med.com

Protembis

Protembis is a medical device start-up company with its headquarters in Aachen, Germany. The company develops a novel left radial cerebral protection device for use during TAVI and other cardiac interventions – the ProtEmbo System. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVI away from the cerebral circulation. The initial safety and feasibility of the ProtEmbo could be demonstrated in a first-in-human study. Imaging data suggests that the ProtEmbo can decrease the risk of brain injury by up to 90 percent.

Karl v. Mangoldt and Conrad Rasmus, Managing Directors
info@protembis.com
tel. +49 241 99033622
www.protembis.com

The National Institute of Cardiology “Dr. Ignacio Chávez”

The National Institute of Cardiology “Dr. Ignacio Chávez” is the largest and most important cardiovascular center in Mexico. As part of the National Institutes of Health it is primarily devoted to patient care, teaching, basic and clinical research as well as to the development of new cardiovascular technologies for the Mexican population. Our motto : Science and love at the service of the heart.

Dr. Marco Antonio Martínez-Ríos, General Director

mtzrios@cardiologia.org.mx

Dr. Arturo Abundes-Velasco, Head, Biotechnological development department

abundesva@yahoo.com.mx

Dr. Eduardo A. Arias, TAVI development project

dreduardoarias@gmail.com

www.cardiologia.org.mx

Trisol Medical

Trisol Medical is a medical device company, which develops a novel transcatheter replacement valve for the treatment of Tricuspid Regurgitation. The Trisol Medical valve is constructed of a nitinol frame with specially designed dome-shaped leaflet. Trisol Medical valve is the first transcatheter therapy, which provides a comprehensive solution to Tricuspid Regurgitation while preserving the Right Ventricle function. Trisol Medical technology was successfully demonstrated in pre-clinical trials. Trisol Medical team is comprised of individuals which hold tens of years of experience in managing and developing medical devices and transcatheter valves. Trisol Medical is based in Yokneam, Israel.

Ron Davidson, CEO

rond@trisol-medical.com

www.trisol-medical.com